Biotech Firm PrimeGen Set to Go Public via SPAC Deal: PRMG

[Para 1: The Lead] PrimeGen Therapeutics, a leading biotechnology firm focusing on genetic diseases (PRMG), is set to go public through a Special Purpose Acquisition Company (SPAC) deal, scheduled for February 15, 2026. The SPAC, previously announced in December 2025, will see PrimeGen raising $100 million at an estimated valuation of $500 million, significantly boosting its financial profile and market presence. [Para 2-3: Supporting details & Context] The transaction is expected to close by the end of this month, marking a pivotal moment for PrimeGen, which has been developing innovative treatments for rare genetic disorders. Financial figures indicate a 30% increase in R&D spending in the last fiscal year, reflecting the company's commitment to advancing its pipeline. Shares of PRMG are anticipated to begin trading on the Nasdaq under the ticker PRMG, signaling a significant step in its journey towards public market scrutiny and expanded capital base.